• Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. 2002. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62: 36093614.
  • Bataille R, Harousseau JL. 1997. Multiple myeloma. N Engl J Med 336: 16571664.
  • Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. 2005. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/Ionization time-of-flight mass spectrometry. Clin Chem 51: 973980.
  • Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JTC, Wang HM, Liao CT, Chen IH. 2005. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 51: 22362244.
  • Cho WC, Yip TT, Yip C, Yip V, Thulasiraman V, Ngan RK, Yip TT, Lau WH, Au JS, Law SC, Cheng WW, Ma VW, Lim CK. 2004. Identification of serum amyloid A protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10: 4352.
  • Dan A, Delmiro FR, Marios CP, Sergio AR, Mark H, Alison L, Edward TJS, Achim S, Richard P, Charlotte FJR, Sanjeev K. 2006. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368: 10121021.
  • Diamandis EP. 2002. Proteomic patterns in serum and identification of ovarian cancer. Lancet 360: 170.
  • Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. 2003. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 3: 14951499.
  • Howard BA, Wang MZ, Campa MJ, Corro C, Fitzgerald MC, Patz EF Jr. 2003. Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3: 17201724.
  • Hussein MA, Juturi JV, Lieberman I. Multiple myeloma: present and future. 2002. Curr Opin Oncol 14: 3135.
  • Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M. 2004. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10: 860868.
  • Kyle RA, Rajkumar SV. 2004. Multiple myeloma. N Engl J Med 351: 18601873.
  • Menon U, Jacobs I. 2002. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16: 469482.
  • Ocqueteau M, Orfao A, Almeida J, Blade' J, Gonzalez M, Ramon GS, Consuelo LB, Maria JM, Hernandez J, Escribano L, Caballero D, Rozman M, San Miguel JF. 1998. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance (MGUS) patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 152: 16551664.
  • Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. 2002. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572577.
  • Ren Y, He QY, Fan J, Jones B, Zhou Y, Xie Y, Cheung CY, Wu A, Chiu JF, Peiris JS, Tam PK. 2004. The use of proteomics in the discovery of serum biomarkers from patients with severe acute respiratory syndrome. Proteomics 4: 34773484.
  • San Miguel JF, Gutiérrez NC, Mateo G, Orfao A. 2006. Conventional diagnostics in multiple myeloma. Eur J Cancer 42: 15101519.
  • Sinz A, Kalkhof S, Ihling C. 2005. Mapping protein interfaces by a trifunctional cross-linker combined with MALDI-TOF and ESI-FTICR mass spectrometry. J Am Soc Mass Spectrom 16: 19211931.
  • Sirohi B, Powles R. 2004. Multiple myeloma, seminar. Lancet 363: 875887.
  • The International Myeloma Working Group. 2003. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749757.
  • Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M Mueller G A, Mueller CA, Flad T. 2004. Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84: 845856.
  • Zhang XY, Leung SM, Morris CR, Shigenaga MK. 2004. Evaluation of a novel, integrated approach using functionalized magnetic beads, bench-top MALDI-TOF-MS with prestructured sample supports, and pattern recognition software for profiling potential biomarkers in human plasma. J Biomol Tech 15: 167175.
  • Zheng PP, Luider TM, Pieters R, Avezaat CJ, van den Bent MJ, Sillevis Smitt PA, Kros JM. 2003. Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. J Neuropathol Exp Neurol 62: 855862.
  • Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P. 2004. New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J Gastroenterol 10: 23272329.